Università degli Studi di Napoli Federico II

PhD in Biotechnology - 40<sup>th</sup> cycle

Dr. Ivelina Ivaylova Dzhambazova

## Advanced next-generation cell factories for the conversion of lignocellulosic biomasses into highvalue bioproducts

Tutors: Prof. Cinzia Pezzella

Department: Dipartimento di Scienze Chimiche

The shift toward a circular bioeconomy requires sustainable biomanufacturing. In this context, *Haloferax mediterranei* emerged as a natural producer of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV)<sup>1</sup> and the carotenoid bacterioruberin<sup>2</sup>, making it a promising candidate for Next-Generation Industrial Biotechnology (NGIB)<sup>3</sup>. However, key industrial bottlenecks remain, including inefficient biomass pretreatment, restricted C-5 sugar utilization, metabolic trade-offs in co-production, and costly recovery processes.

This PhD project focuses on optimizing *H. mediterranei* as a next-generation microbial cell factory. The approach includes (i) developing green pretreatment techniques for efficient sugar recovery, (ii) integrating omics and genetic engineering to enhance PHBV and bacterioruberin synthesis, while fine-tuning HV content for improved material properties, (iii) designing bio-based extractions and developing morphology engineering strategies for streamlined downstream processing, and (iv) developing PHBV-bacterioruberin bio-composites with antioxidant properties.

This research aims to improve the efficiency of biopolymer and carotenoids production, expanding their potential for biomaterial and cosmeceutical applications.

## References

- 1. Koller, M. Polyhydroxyalkanoate biosynthesis at the edge of water activitiy-haloarchaea as biopolyester factories. *Bioengineering* (2019)
- 2. Martínez-Espinosa, R. M. Halocins and C50 Carotenoids from Haloarchaea: Potential Natural Tools against Cancer. *Marine Drugs 2024, Vol. 22, Page 448* **22**, 448 (2024).
- 3. Chen, G. Q. & Jiang, X. R. Next generation industrial biotechnology based on extremophilic bacteria. *Curr Opin Biotechnol* **50**, 94–100 (2018).